Plasma Fractionation Market Size, Share, Growth Factors, Competitive Landscape, with Regional Forecast to 2035
The global plasma fractionation market is poised for significant growth, with its size estimated to expand from approximately USD 4.8 billion in 2024 to USD 12.7 billion by 2035, reflecting a compound annual growth rate (CAGR) of 9.2% during this period. This growth is driven by the rising prevalence of rare and chronic disorders affecting over 410 million people worldwide, which has increased the demand for plasma-derived therapies as effective treatment options.
Market Overview and Growth Drivers
Plasma fractionation is a critical process that separates and purifies key blood plasma components such as immunoglobulins, albumins, anticoagulant factors, and protease inhibitors. These purified fractions are essential for formulating lifesaving therapeutics, especially for patients with rare and complex diseases. The United States dominates plasma donation, hosting about 80% of the world’s plasma donation centers and supplying over 70% of plasma used for fractionation globally. The demand for plasma-derived therapies is further fueled by ongoing advancements in fractionation technologies and plasma manufacturing processes, which aim to improve access and efficacy.
Segmentation and Therapeutic Applications
The plasma fractionation market is segmented by type of company (in-house manufacturers and contract service providers), scale of operation (preclinical, clinical, commercial), types of plasma-derived therapeutic products (albumins, coagulation factors, immunoglobulins, protease inhibitors, and others), and therapeutic areas (hematological, hepatic, immunological, neurological disorders, and others). Immunoglobulins represent the largest segment, capturing over 45% of the market share, due to their broad use in treating neurological, immunological, and hematological diseases. The increasing prevalence of immunological disorders and immunodeficiency diagnoses is expected to sustain high demand for immunoglobulin therapies.
Geographical Insights
North America currently holds the largest share of the plasma fractionation market, generating close to 45% of demand, supported by a well-established plasma collection infrastructure and high awareness of plasma-derived products. Meanwhile, the Asia-Pacific region is the fastest-growing market, projected to grow at an annualized rate exceeding 11% by 2035. This growth is attributed to the region’s large consumer base and the presence of key manufacturers in countries such as China, India, Australia, and South Korea.
Market Landscape and Key Players
The plasma fractionation market is consolidated, with large commercial fractionators acquiring smaller regional players to expand capacity and capabilities. Over 35 companies currently perform in-house plasma fractionation, with more than 85 plasma fractionation facilities worldwide, predominantly in Asia-Pacific, Europe, and North America. Leading companies include CSL Behring, Grifols, Takeda Pharmaceutical, Baxter, Kedrion, and Octapharma. These companies have also been expanding their plasma collection networks through acquisitions, such as Takeda’s acquisition of BioLife Plasma Services and Grifols’ acquisition of Prometic Plasma Resources Inc’s donation center in Canada.
Challenges and Recent Developments
The COVID-19 pandemic caused a roughly 20% decline in plasma donations, leading to raw material shortages for plasma-derived therapies. To counter this, stakeholders including government agencies and patient advocacy groups have launched campaigns to encourage plasma donation. Technological innovations, such as CSL Plasma’s adoption of the Rika Plasma Donation System, which reduces donation time by 30%, are improving donor experience and collection efficiency. Recent investments include PlasmaGen Biosciences raising INR 225 crores for a new manufacturing facility and SK Plasma securing USD 50 million to build a fractionation plant.
Future Outlook
The plasma fractionation market is expected to continue its robust growth trajectory, supported by increasing demand for plasma-derived therapies, technological advancements in fractionation and manufacturing, and expanding plasma collection infrastructure globally. The market’s evolution will be shaped by ongoing mergers and acquisitions, capacity expansions, and the development of new plasma-derived products to address a broadening range of therapeutic areas.
Read More :-
https://www.rootsanalysis.com/reports/plasma-fractionation-market.html
Plasma Fractionation Market Size, Share, Growth Factors, Competitive Landscape, with Regional Forecast to 2035
The global plasma fractionation market is poised for significant growth, with its size estimated to expand from approximately USD 4.8 billion in 2024 to USD 12.7 billion by 2035, reflecting a compound annual growth rate (CAGR) of 9.2% during this period. This growth is driven by the rising prevalence of rare and chronic disorders affecting over 410 million people worldwide, which has increased the demand for plasma-derived therapies as effective treatment options.
Market Overview and Growth Drivers
Plasma fractionation is a critical process that separates and purifies key blood plasma components such as immunoglobulins, albumins, anticoagulant factors, and protease inhibitors. These purified fractions are essential for formulating lifesaving therapeutics, especially for patients with rare and complex diseases. The United States dominates plasma donation, hosting about 80% of the world’s plasma donation centers and supplying over 70% of plasma used for fractionation globally. The demand for plasma-derived therapies is further fueled by ongoing advancements in fractionation technologies and plasma manufacturing processes, which aim to improve access and efficacy.
Segmentation and Therapeutic Applications
The plasma fractionation market is segmented by type of company (in-house manufacturers and contract service providers), scale of operation (preclinical, clinical, commercial), types of plasma-derived therapeutic products (albumins, coagulation factors, immunoglobulins, protease inhibitors, and others), and therapeutic areas (hematological, hepatic, immunological, neurological disorders, and others). Immunoglobulins represent the largest segment, capturing over 45% of the market share, due to their broad use in treating neurological, immunological, and hematological diseases. The increasing prevalence of immunological disorders and immunodeficiency diagnoses is expected to sustain high demand for immunoglobulin therapies.
Geographical Insights
North America currently holds the largest share of the plasma fractionation market, generating close to 45% of demand, supported by a well-established plasma collection infrastructure and high awareness of plasma-derived products. Meanwhile, the Asia-Pacific region is the fastest-growing market, projected to grow at an annualized rate exceeding 11% by 2035. This growth is attributed to the region’s large consumer base and the presence of key manufacturers in countries such as China, India, Australia, and South Korea.
Market Landscape and Key Players
The plasma fractionation market is consolidated, with large commercial fractionators acquiring smaller regional players to expand capacity and capabilities. Over 35 companies currently perform in-house plasma fractionation, with more than 85 plasma fractionation facilities worldwide, predominantly in Asia-Pacific, Europe, and North America. Leading companies include CSL Behring, Grifols, Takeda Pharmaceutical, Baxter, Kedrion, and Octapharma. These companies have also been expanding their plasma collection networks through acquisitions, such as Takeda’s acquisition of BioLife Plasma Services and Grifols’ acquisition of Prometic Plasma Resources Inc’s donation center in Canada.
Challenges and Recent Developments
The COVID-19 pandemic caused a roughly 20% decline in plasma donations, leading to raw material shortages for plasma-derived therapies. To counter this, stakeholders including government agencies and patient advocacy groups have launched campaigns to encourage plasma donation. Technological innovations, such as CSL Plasma’s adoption of the Rika Plasma Donation System, which reduces donation time by 30%, are improving donor experience and collection efficiency. Recent investments include PlasmaGen Biosciences raising INR 225 crores for a new manufacturing facility and SK Plasma securing USD 50 million to build a fractionation plant.
Future Outlook
The plasma fractionation market is expected to continue its robust growth trajectory, supported by increasing demand for plasma-derived therapies, technological advancements in fractionation and manufacturing, and expanding plasma collection infrastructure globally. The market’s evolution will be shaped by ongoing mergers and acquisitions, capacity expansions, and the development of new plasma-derived products to address a broadening range of therapeutic areas.
Read More :- https://www.rootsanalysis.com/reports/plasma-fractionation-market.html